FDA Warning Letter Novo Nordisk Reveals Serious...

By João L. Carapinha

March 11, 2026

The U.S. Food and Drug Administration (FDA) issued the FDA Warning Letter Novo Nordisk
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Surge in Obesity Intervention Costs in the Netherlands
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
Weight Loss: Advances in Hormone-Based Obesity Treatments
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Obesity Health Economics: Forecasting Trends and Costs in the US
Evolving Burden of Obesity in the US: Key Insights on Obesity Prevention Stra...